Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology Inc. (VIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 2,380,715 | $13,593,883 | 0.32% | |
| 2. | Millennium Management Israel Englander | 1,396,504 | $7,974,038 | +130% | 0% |
| 3. | Renaissance Technologies Jim Simons | 1,167,100 | $6,664,141 | +10% | 0.01% |
| 4. | Hudson Bay Capital Management Sander Gerber | 911,882 | $5,206,846 | +32% | 0.02% |
| 5. | Citadel Investment Group Ken Griffin | 799,034 | $4,562,484 | -77% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | $56,815.50 | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | $62,395.50 | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | $63,136.25 | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | $63,992.50 | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | $499.85 | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.56 | 6,799 | $37,782.04 | 110,701 | 2025-11-17 | Filing | |
| $5.16 | 2,385 | $12,306.60 | 78,210 | 2025-11-05 | Filing | |
| $5.86 | 1,365 | $8,003.00 | 80,595 | 2025-11-03 | Filing | |
| $5.64 | 22,000 | $124,047.00 | 1,210,391 | 2025-11-03 | Filing | |
| $6.49 | 100 | $649.00 | 14,573,983 | 2025-10-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,684,041 | $95,265,874 | 0.72% | |
| 2. | 15,967,656 | $91,175,315 | 0% | |
| 3. | 12,916,663 | $73,754,146 | 14.98% | |
| 4. | 12,799,381 | $73,084,465 | 0% | |
| 5. | 5,241,293 | $29,927,783 | 0% |
News See All
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology's Second Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology's First Quarter 2025 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript
Operator: [Call starts abruptly] …Vir's Third Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s Second Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s First Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.86, expectations were $-1.14. Vir Biotechnology, Inc.